New marine derived anticancer therapeutics ─ A journey from the sea to clinical trials

Marine Drugs

Volumn 2, Issue 1, 2004, Pages 14-29

  Jimeno, J ^a   Faircloth, G ^b   Sousa Faro, J M Fernández ^a   Scheuer, P ^c   Rinehart, K ^d  

^a PHARMAMAR S A   (Spain)

^b PharmaMar USA Inc   (United States)

^c University of Hawaii   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

AplidinR; Cancer treatment; ET 743; Kahalalide F; Marine drugs

Indexed keywords

EID: 11844262569     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md201014     Document Type: Review

References (71)

1. Monnier, C. Les plantes Medicinales. Vertus et Traditions; Privat Eds. Toulouse 2002.
2. Sweldlow, J. Nature and Medicine; National Geographic Mil Eds.: Paris, 2000.
3. Ellis, R. Aquagenesis. The origin and evolution of life in the sea; Viking Eds.: New York, 2001.
4. Macdougall, J.D. A short history of Planet Earth; John Wiley Eds.: New York, 1996; p. 5.
5. Argulis, L., Schwartz, K. Five Kingdoms, an illustrated guide to the phyla of life on Earth; W.H.
6. Freeman & Company: New York, 1982; pp. 16-17.
7. Scotfield, V.I.; Schumpberger, J.M.; West, L.A.; Weissman, L. Protocordate allorecognition is controlled by aq MHC-like gene. Nature 1982, 295, 499-502.
8. Pendergast, R.A.; Lutty, G.A.; Scott, L. Direct inflammation: the phylogeny of lymphokines. Dev. Comp. Inmunol. 1983, 7, 629-632.
9. Ruggieri, G.D. Drugs from the sea. Science 1976, 194, 491-496.
10. Haefner, B. Drugs from the deep. Marine natural products as drug candidates. Drug Discov. Today 2003, 8, 536-544.
11. Sorriente A. Manoalide. Current Med.Chemistry 1999, 6, 415-431.
12. Longley, R.; Cardigan, D.; Harmody, D.; Gunasereka, M.; Gunasereka, S. Discodermolide-A new marine derived Inmunosuppressive compound. Transplantation 1991, 52, pp. 650-661.
13. Angerhofer, C.; Pezzuto, J.; Konig, G.; Wright, A.; Sticcher O. Antimalarial activity of Sestiperquenes from the marine sponge Acanthella klelthra. J. Nat. Prod. 1992, 55, 1787-1789.
14. Nagai, H., Murata, M., Torigoe, K., Sakate, M., Yasumoto, T. Gambieric acids, New potent antifungal substances with unprecedent polyether structures from a marine dinoflagelate Gambiercus toxicus. J. Org. Chem. 1992, 57, 5448-5453.
15. Alonso, D.; Khalil, Z.; Satkunanthan, N.; Livett, B.G. Drugs from the Sea: Conotoxins as Drug Leads for Neuropathic Pain and Other Neurological Conditions. Min. Rev. Med. Chem. 2003, 3, 785-787.
16. Craigg, G.M.; Newman, D.J.; Weiss, R.B. Coral reefs, forests and thermal vents: The worldwide exploration of nature for novel antitumor agents. Semin. Oncol. 1997, 24, 156-163.
17. Bergmann, W.; Feeney, R.J. Contributions to the study of marine products. The nucleosides of sponges III. Spongothymidine and Spongouridine J. Org. Chem. 1985, 20, 1501-1507.
18. Wolf, S.N.; Marion, J.; Stein, R.S. High dose cytosine arabinoside and daunorubicin as consolidation therapy for acute non lymphoblastic leukemia. Blood. 1985, 65, 1407-1411.
19. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma: a review. Cancer. 1996, 78(3), 633-637.
20. Guchelaar H.J., Richel Dj., Van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer. Treat. Rep. 1996, 22, 15-31.
21. Mayer AMS, Gustaveson KR. Marine pharmacology in 2000: antitumor and cytotoxic compounds. Int J Cancer. 2003, 105, 291-299.
22. Amador M, Jimeno J., Paz Ares L., Cortés Funes H., Hidalgo M. Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol. 2003, 14(11): 1607-1615.
23. Rinehart K.L., Holt T.G., Fregau N.L. Ecteinascidins 729, 743, 745, 759ª, 759b and 770. Potent antitumor compounds from the Caribbean tunicate Ecteinascidia Turbinata. J Org Chem. 1990, 55(15), 4515-4516.
24. Jimeno J.M., Fairlocth G., Cameron L. Cameron L., Vega E., Meely K., Rinehart K., Fernandez-Sousa, JM. Progress in the acquisition of new marine derived anticancer compounds: development of ecteinascidin-743 (ET-743). Drugs of the Future. 1996, 21(11), 1155-1165.
25. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'incalci M And Mantovani R: Interference of transcriptional activation by the anti-neoplastic drug ET-743. Proc.Natl.Acad.Sci.USA. 2000, 97: 6780-6784.
26. Jin S, Gorfajn B, Faircloth G And Scotto K: Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc.Natl.Acad.Sci.USA. 2000, 97, 6775-6779.
27. Friedman D, Hu Z, Kolb EA, Gorfajn B And Scotto KW: Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 2002, 62, 3377-3381.
28. Kanzaki A, Takebayashi Y, Ren XQ, Akiyama S., Bates S., Pommier Y.,: Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther. 2002, 1, 1327-1334.
29. Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth G T; Liberi G; Foiani M; D'Incalci M: Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001, 92, 583-588.
30. Takebayashi Y; Pourquier P; Zimonjic D B; Nakayama K; Emmert S; Ueda T; Urasaki Y; Kanzaki A; Akiyama S I; Popescu N; Kraemer K H; Pommier Y: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001, 7, 961-966.
31. D'incalci M, Colombo T, Ubezio P., Nicoletti I., Giavazzi R., Erba E., Ferrarese L., Meco D., Riccardi R., Sessa C., Cavallini E., Jimeno J., Faircloth G: The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer. 2003, 39, 1920-1926.
32. Sarries C., Haura E., Roig B. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics. 2002, 3(6), 763-780.
33. Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, Rosing H, Jimeno J, Cvitkovic E.: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001, 19, 1256-1265.
34. Ryan DP, Supko JG, Eder JP, Seiden M, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001, 7, 231-242.
35. Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK.: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002, 8, 75-85.
36. Twelves C., Hoekman K., Bowman A., Vermorken J.B., Anthoney A., Smyth J., Van Kesteren C., Beijnen J.H., Uiters J., Wanders J., Gomez J., Guzmán C., Jimeno J., Hanauske A..: Phase I and pharmacokinetic study of Yondelis (Ecteinascidin 743; ET-743) administered as an infusion over 1h or 3h every 21 days in patients with solid tumors. Eur J Cancer. 2003, 39, 1842-1851.
37. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol. 2001, 19(5), 1248-1255.
38. Demetri G., Manola J., Harmon D., Maki R., Seiden R., Supko J., Ryan D., Puchlaski T., Goss G., Merriam P., Waxman A., Slater S., Potter A., Quigley T., Lopez T., Sancho MA., Guzman C., Jimeno J., Garcia Carbonero R. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of Phase II and Pharmacokinetic studies in the U.S.A American Society of Clinical Oncology, San Francisco, CA, May 12 – 15,.2001. Procc. 352a. Abstract 1406.
39. Le Cesne A., Blay J.,. Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Donato De Paola E, Van Glabbeke M., Jimeno J., Nielsen O. ET-743 is an active drug in adult soft-tissue sarcoma: a STBSG-EORTC Phase II trial. American Society of Clinical Oncology, 37th Annual Meeting. San Francisco, CA, May 12 – 15, 2001. Procc. 353a. Abstract 1407.
40. Yovine A., Riofrio M., Brain E., Blay JY., Kahatt C., Delaloge S., Beautier L., Cottu P., Jimeno J., Cvitkovic E., Misset JL. Ecteinascidin-743 given as a 24 hour (H) intravenous continuos infusion (IVCI) every 3 weeks: results of a Phase II trial in patients (PTS) with pretreated soft tissue sarcomas (PSTS). American Society of Clinical Oncology. 37th Annual Meeting. San Francisco, CA, May 12 – 15, 2001. Proc. 363a. Abstract 1449.
41. Jimeno J., Maki R., Casali P., Faircloth G., Martinez N., Nieto A., Cañigueral S. Therapeutic impact of ET-743 (Yondelis®, Trabectidin) a new marine derived compound in Sarcoma. Current Opinion in Orthopedics. Submitted September 2003.
42. Zelek L., Yovine A., Brain E., Jimeno J., Taamma A., Martin C., Spielmann M., Civtkovic E., Misset JL. “Ecteinascidin 743 in pretreated/advanced metastatic breast cancer patients: Preliminary results with the 24 hours infusion schedule”. Procc. ASCO New Orleans 2000, pp 149, abst 592.
43. Gómez J., López-Lázaro L., Guzmán C., González A., Misset J.L., Twelves C., Bowman A., Hoekman K., Villalona M., Ryan D., Paz-ares L., Jimeno J. “Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743”. ASCO New Orleans 2000, Procc. Abst 727:187ª.
44. Lopez Martin J.A., Nieto A., Demetri G., Misset JL., Ray-Coquard I., Guzman C., Sancho MA., Parra MC., Ibarra I., Millan S., Martín C., Ruiz A., De Alvaro J., Lopez-Lazaro L., Gomez J., Jimeno J..: Safety profile of ecteinascidin-743 (ET-743) in phase II clinical trials (CT)in adult patients with solid tumors. Proc Am Soc Clin Oncol. 2002, 21: 96a.
45. Colombo N., Capri G., Bauer J., Noberasco C., De Braud F., Grasselli G., Jimeno J., Ruiz A., Corradino I., Marsoni S., Sessa C. Phase II and Pharmacokinetics study of 3 hour infusion of ET743 in ovarian cancer patients failing platinum-taxanes. ASCO 38th Annual Meeting, Orlando, Florida, May 18-21, 2002, Proc. p.221a, Vol., 21, Abstract 880.
46. Casali P., Casanova N., Dileo P., Ferrari S., Bacci G., Picci P., Marsoni S., Jimeno J., Riccardi R., Gianni L. Activity of Ecteinascidin 743 (ET-trabectedin 743) 3 h infusion in adult and childhood small round cell sarcomas. ASCO 39th Annual Meeting, Chicago IL, May 31-June 3, 2003,Proc Vol. 22 Abs. 962 pp 240.
47. Forouzesh B., Hidalgo M., Denis L., Schwart G., Hammond L., Monroe P., Guzman C., Lopez-Lazaro L., Supko J., Jimeno J., Rowinsky E. phase I and pharmacokinetic study of the marine-derived DNA minor groove binder ET-743 on a weekly x3 every-4-week schedule in patients with advanced solid malignancies. Proc of AACR-NCI-EORTC International Conference on Molecul targets and cancer therapeutics: Discovery, Biology and Clinical applications. Miami Beach, October 29-November 2, 2001, 42.
48. Grasselli G., Malossi A., Marsoni S., Colombo N., Perez C., Zucchetti M., D’incalci M., Lopez Martin JA., Jimeno J, Capri G., Raspagliesi F., Curigliano G., Gianni L., Sessa C. Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors. Proc Am Soc Clin Oncol 2003 22: N°542.
49. Rinehart K.L., Gloer J.B., Cook J.C., Mizsak S.A., Scohill T.A., “Structures of the Didemnins, Antiviral and Cytotoxic Depsipeptides from a Caribbean Tunicate”. J Am Chem Soc., 1981, 103, 1857-1859.
50. Erba E., Bassano L., Di Liberti G., Muradore I., Chiorino G., Ubezio P., Vignati S., Codegoni A., Desiderio A., Faircloth G., Jimeno J., D’Incalci M. Cell Cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer. 2002, 86:1510-17.
51. Broggini M, Marchini S., Borsott P., Galliera E., Erba E., Taraboletti G., Giavazzi R., Jimeno J., Faircloth G., D’incalci M. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-9.
52. Anthoney A., Paz-Ares L., Twelves C., Cortes-Funes H., Kaye S., Pronk L., Celli N., Lopez-Lazaro L., Guzman C., Jimeno J. Phase I and Pharmacokinetic (PK) Study of APL (APL) Using a 24-Hour, Weekly Schedule. Proc Am Soc Clin Oncol. 2000; abstract #734
53. Ciruelos E.M., Twelves C., Dominguez M.J., Mckay H., Anthony, A. Castellanos D., Bezares S., Ruiz A., Lopez-Lazaro L., Jimeno J., Celli C., Cortes-Funes H., Paz-Ares L. Phase I clinical and pharmacokinetic study of the marine compound APL (APL) administered as a 3 hour infusion every 2 weeks. Proc Am Soc Clin Oncol. 2002, abstract # 422. 53 Bowman A., Izquierdo M.A., Jodrell D., Martinez M., Cicchella B., Jimeno J., Guzman C., Germa-Lluch J., Celli N., Smyth J. Phase I Clinical and Pharmacokinetic (PK) Study of the Marine Compound APL (APL), administered as a 1 Hour Weekly Infusion. Proc Am Soc Clin Oncol. 2001, abstract #476.
54. Armand J.P., Ady-Vago N., Faivre S., Chieze S., Baudin E., Ribrag V., Lecot F., Iglesias L., López-Lázaro L., Guzmán C., Jimeno J., Ducreux M., Le Chevalier T., Raymond E. Phase I and Pharmacokinetic Study of APL Given as a 24-Hour Continuous Infusion Every Other Week (q2w) in Patients (pts) with Solid Tumor (ST) and Lymphoma (NHL). Proc Am Soc Clin Oncol. 2001, abstract #477
55. Maroun J.A., Goel R., Stewart D.J., Tomiak E., Belanger K., Soulieres D., Charpentier D., Seymour L., Matthews S., Jimeno J., Guzman C. Phase I Study of APL in a 5 Day Bolus Q 3 Weeks in Patients with Solid Tumors and Lymphomas. Proc Am Soc Clin Oncol 2001; abstract #2082
56. Bresters D., Broekhuizen A., Faircloth G., Jimeno J., Kaspers G. In vitro cytotoxicity of Aplidine and cross-resistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples; a rational basis for clinical development. Leukemia. 2003, 1-6.
57. Erba E., Serafini M., Gaipa G., Tognon G., Marchini S., Muradore I., Celli N., Rotilio D., Broggini M., Jimeno J., Faircloth G., Biondi A., D’incalci M. The effect of Aplidine in acute lymphoblastic leukaemia cells. Br J Cancer Suppl. 2003, 89, 763-773.
58. Raymond E, Paz-Ares L, Izquierdo MA, Pardo B, Ciruelos E, Baudin E, Domínguez MJ, Martinez M, Jimeno J, Lopez-Martin JA. Activity of APL, a new marine compound, against medullary thyroid carcinoma (MTC): Phase I trials as screening tools for rare tumors. Ann Oncol. 2002; 13 (Suppl. 5): page 22.
59. Hamann MT, Otto CS, Scheuer PJ, “Kahalalides: Bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp.”, J. Org. Chem, 1996, 61, 6594-660.
60. Hamann MT, Scheuer PJ, “Kahalalide F: A bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp.”, J Am Chem Soc. 1993,115, 5825-5826.
61. García-Rocha M, Bonay P, Avila J, “The antitumor compound Kahalalide F acts on cell lysosomes”, Cancer Lett, 1996, 99, 43-50.
62. Suarez Y., Gonzalez L., Cuadrado A., Berciano M., Lafarga M., Muñoz A. Kahalalide F, a new marine derived compound induces oncosis in human prostate and breast cancer cells. Mol. Cancer Therapeutics, 2003, 863-872.
63. Supko J.G, Lu H., Jimeno J.M., Grant W., Faircloth G.T. “Preclinical pharmacology studies with the marine natural product Kahalalide F”. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 16-19, 1999. Washington D.C. Abstract no. 315.
64. Ciruelos E., Trigo JM., Pardo B., Paz-Ares L., Estaun N., Cuadra C., Domínguez MJ., Marin A., Ruiz A., Jimeno J., Izquierdo MA. A phase I clinical and pharmacokinetic (PK) study with KahalalideF (KF) in patients (pts) with advanced solid tumours (AST) with a continuous weekly (W) 1-hour iv infusion schedule. 14th NCI-EORTC-AACR Congress, Frankfurt, Germany. European Journal of Cancer, 19-22 November 2002, Vol 38, Supplement 7, pp S33, Abstract 95.
65. Schellens J.H.M., Rademakerlakhai J.M., Horenblas S., Meinhardt W., Stokvis E., M.De Reijke T., Jimeno J., Lopez-Lazaro L., Lopez-Martin J.A., Beijnen J.H. Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen resistant prostate cancer ASCO 38th Annual Meeting. Orlando, Florida, May 18-21, 2002, Proc.113a, Vol., 21, Abstract 451.
66. Cuevas C; Perez M; Martin M J; Chicharro J L; Fernandez-Rivas C; Flores M; Francesch A; Gallego P; Zarzuelo M; de La Calle F; Garcia J; Polanco C; Rodriguez I; Manzanares I. Síntesis of Ecteinascidin ET-743 and phthalascidin PT-650 from syano safracin B. Org. Lett. 2000, 2, 2245-2548.
67. Joug G., Gonzalez L., Albericio F, Lloyd-Williams P, Giralt E. Total síntesis of dehydro didemnin B. Use of uranium and phosphonium salt coupling reagents in peptide synthesis in solution. J. Org. Chem. 1997, 62, 354-366.
68. Lopez Macia A., Jiménez JC, Royo M., Giralt E., Albericio F. Synthesis and structure determination of Kahalalide F. Am. Chem Society. 2001, 123, 11398-11401.
69. Cuadros R., Montejo De Garcini E., Wandosell F., Faircloth G., Fernández Sousa JM, Avila J. The marine compound Spisulosine, and inhibitor of cell proliferation promotes the disassembly of actin stress fibers. Cancer Lett. 2000, 152. 23-29.
70. Jimeno J., García-Grávalos D., Ávila J., Smith B., Grant W. And Faircloth G.T. ES-285, a marine natural product with activity against solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Washington D.C., November 16-19, 1999, Abstract no. 314.
71. Sanchez Beato M., Moneo V, Martínez N, Fernández I, Carnero A, Piris MA, Jimeno J. Molecular pharmacodynamic (MPD) effects induced by ET-743 (Yondelis) in human sarcoma cells (HSC). Procc International Conference on Applied Genomics – 9th ESCAP/16th ISDQP Meeting, Amsterdam, The Netherlands. October 1-4, 2003, Abstract C-14 p. 65.